We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Unveils Proton Treatment Planning Eclipse v16 System
Read MoreHide Full Article
Varian recently launched its treatment planning system, Eclipse v16, leveraging its Intelligent Cancer Care approach in developing new solutions that utilize advanced technologies like machine learning. The company has received CE mark for the system while the FDA 510(K) clearance for the same is pending.
The launch of this system is a step forward in Varian’s commitment toward strengthening its Proton Solutions segment.
More About the System
This new system constitutes of intelligent features such as RapidPlan PT (the first clinical application of machine learning in proton treatment planning) and RT Peer Review, which is a collaborative workspace developed to simplify and boost the peer review process for radiotherapy treatment plans.
RapidPlan is a knowledge-based treatment planning software that helps healthcare experts use data from similar existing treatment options in order to develop high-quality personalized plans for patients quickly. This knowledge-based planning software is now being used for proton treatment planning along with RapidPlan PT. The software also enables dose prediction with machine learning models that can be utilized as a support tool to decide which patients would be ideal for proton or photon-based therapy.
The machine learning in RapidPlan PT is equipped to diminish proton treatment plan optimization from a one to eight hour process, to less than 10 minutes. The RT Peer Review feature in Eclipse v16 has been developed so that the oncology community can smoothly integrate this review process into their routine clinical workflow by automatically presenting the requisite information.
Notably, Varian is the first vendor in the industry that offers machine learning capability in both proton and photon treatment planning.
Recent Developments
In March, Varian announced that Proton International at University of Alabama has successfully treated its first cancer patient using the Varian ProBeam Compact proton therapy system.
Market Prospects
Per a report published by P&T community, the global proton therapy market is projected to see a CAGR of 13.91% during the 2019-2023 period. Hence, the launch of this system seems well-timed.
Price Performance
In the past year, the stock has lost 27.6% compared with the 12.2% decline of its industry.
Zacks Rank and Key Picks
Varian carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , QIAGEN N.V.(QGEN - Free Report) and Integra LifeSciences Inc (IART - Free Report) .
QIAGEN’s long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2.
Integra’s long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Varian Unveils Proton Treatment Planning Eclipse v16 System
Varian recently launched its treatment planning system, Eclipse v16, leveraging its Intelligent Cancer Care approach in developing new solutions that utilize advanced technologies like machine learning. The company has received CE mark for the system while the FDA 510(K) clearance for the same is pending.
The launch of this system is a step forward in Varian’s commitment toward strengthening its Proton Solutions segment.
More About the System
This new system constitutes of intelligent features such as RapidPlan PT (the first clinical application of machine learning in proton treatment planning) and RT Peer Review, which is a collaborative workspace developed to simplify and boost the peer review process for radiotherapy treatment plans.
RapidPlan is a knowledge-based treatment planning software that helps healthcare experts use data from similar existing treatment options in order to develop high-quality personalized plans for patients quickly. This knowledge-based planning software is now being used for proton treatment planning along with RapidPlan PT. The software also enables dose prediction with machine learning models that can be utilized as a support tool to decide which patients would be ideal for proton or photon-based therapy.
The machine learning in RapidPlan PT is equipped to diminish proton treatment plan optimization from a one to eight hour process, to less than 10 minutes. The RT Peer Review feature in Eclipse v16 has been developed so that the oncology community can smoothly integrate this review process into their routine clinical workflow by automatically presenting the requisite information.
Notably, Varian is the first vendor in the industry that offers machine learning capability in both proton and photon treatment planning.
Recent Developments
In March, Varian announced that Proton International at University of Alabama has successfully treated its first cancer patient using the Varian ProBeam Compact proton therapy system.
Market Prospects
Per a report published by P&T community, the global proton therapy market is projected to see a CAGR of 13.91% during the 2019-2023 period. Hence, the launch of this system seems well-timed.
Price Performance
In the past year, the stock has lost 27.6% compared with the 12.2% decline of its industry.
Zacks Rank and Key Picks
Varian carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , QIAGEN N.V.(QGEN - Free Report) and Integra LifeSciences Inc (IART - Free Report) .
ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
QIAGEN’s long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2.
Integra’s long-term earnings growth rate is estimated at 11.9%. It currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>